ArticleCureus2025
Influenza Vaccination Rates, Awareness, and Attitudes Among Patients With Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Cross-Sectional Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Vaccination in systemic lupus erythematosus.Human vaccines & immunotherapeutics · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundsThe influenza vaccine is recommended annually for patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). This study aimed to report the influenza vaccination rate among RA and SLE patients who are following up at Dammam Medical Complex (DMC), Dammam, Saudi Arabia, to evaluate their understanding of the influenza vaccine and its benefits, and to assess their attitudes regarding it, including any concerns or misconceptions.
methodsThis was a cross-sectional study. It included all patients with RA and SLE who were following up in the rheumatology clinic at DMC. The study was conducted between November 2024 and February 2025. Data was collected through a self-administered paper questionnaire in the clinic. Descriptive statistics, including mean, standard deviation, counts, and percentages, were computed as required. For comparative analyses, the Chi-square test was employed for categorical variables, while the two-sample t-test was used for continuous variables.
resultsA total of 261 patients participated in the study, including 191 RA patients (73.2%) and 70 SLE patients (26.8%). Out of the total, 131 patients (50.2%) reported that they had been vaccinated against influenza in the past. However, only 72 patients (27.6%) confirmed they had received the vaccine within the last two seasons, whereas a significant majority, 189 patients (72.4%), had not been vaccinated during this timeframe. Regarding the perception of the influenza vaccination's safety and effectiveness, 133 patients (51.0%) affirmed that they believed it to be safe and effective. When asked if the seasonal influenza vaccine is the best method to avoid complications from influenza, 153 patients (58.6%) agreed. Most patients (n = 140, 53.6%) were aware that seasonal influenza vaccination is recommended for individuals with chronic diseases.
conclusionsOur study revealed a low vaccination rate among RA and SLE patients in the last two seasons. To minimize the risk of complications, it is crucial to increase awareness about the benefits of influenza vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.